免疫抑制状態の患者での免疫応答
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
Jensen B, et al. 〔Lancet Reg Health Eur. 2021 Sep;8:100164〕(査読済み)
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
Goshen-Lago T, et al. 〔JAMA Oncol. 2021 Jul 8;e212675〕(査読済み)
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients (Correspondence)
Carr EJ, et al. 〔Lancet. 2021 Sep 18;398(10305):1038-1041〕(査読済み)
Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
Yau K, et al. 〔JAMA Netw Open. 2021 Sep 1;4(9):e2123622〕(査読済み)
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients (Correspondence)
Kamar N, et al. 〔N Engl J Med. 2021 Aug 12;385(7):661-662〕(査読済み)
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses (Research Letter)
Benotmane I, et al. 〔JAMA. 2021 Jul 23;326(11):1063-1065〕(査読済み)
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients (Correspondence)
Hall VG, et al. 〔N Engl J Med. 2021 Sep 23;385(13):1244-1246〕(査読済み)
Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study
Wu JT, et al.〔JAMA Oncol. 2021 Dec 2;e215771〕(査読済み)
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents
Fenioux C, et al.〔JAMA Oncol. 2022 Jan 7;e217777〕(査読済み)
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
Alexander JL, et al.〔Lancet Gastroenterol Hepatol. 2022 Feb 3;S2468-1253(22)00005-X〕(査読済み)